市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | BridgeBio Pharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.93% |
| 机构持股比例 | 98.15% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 72.00 (UBS, 86.43%) | 购买 |
| 中 | 54.00 (39.82%) | |
| 低 | 50.00 (Redburn Atlantic, 29.47%) | 购买 |
| 50.00 (JP Morgan, 29.47%) | 购买 | |
| 平均值 | 57.17 (48.03%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 36.85 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 30 Apr 2025 | 63.00 (63.13%) | 购买 | 38.36 |
| Scotiabank | 30 Apr 2025 | 55.00 (42.41%) | 购买 | 38.36 |
| UBS | 30 Apr 2025 | 72.00 (86.43%) | 购买 | 38.36 |
| HC Wainwright & Co. | 15 Apr 2025 | 53.00 (37.23%) | 购买 | 34.24 |
| Redburn Atlantic | 31 Mar 2025 | 50.00 (29.47%) | 购买 | 34.57 |
| JP Morgan | 24 Mar 2025 | 50.00 (29.47%) | 购买 | 37.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合